NCT01145989 is a Phase 2 clinical trial of AT9283 in Multiple Myeloma, sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT01145989?

NCT01145989 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT01145989?

Interventions in NCT01145989: AT9283.

What condition does NCT01145989 study?

NCT01145989 studies Multiple Myeloma.

Is NCT01145989 still recruiting?

NCT01145989 is currently completed. Last updated 4 August 2023.

Last reviewed 2023-08-04 · How we verify

NCT01145989

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Completed Phase 2 Last updated 4 August 2023

What this trial tests

Phase 2 trial testing AT9283 in Multiple Myeloma in 8 participants. Completed in 27 November 2015.

Timeline

15 February 2011

Primary endpoint
29 October 2014

27 November 2015

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	15 February 2011
Primary completion	29 October 2014
Estimated completion	27 November 2015
Sites	6 locations across Canada

Drugs / interventions tested

AT9283 — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

NCIC Clinical Trials Group

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.
Du R, Huang C, Liu K, Li X, et al · · 2021 · cited 388× · PMID 33451333 · DOI 10.1186/s12943-020-01305-3
Aurora A kinase (AURKA) in normal and pathological cell division.
Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, et al · · 2013 · cited 368× · PMID 22864622 · DOI 10.1007/s00018-012-1073-7
Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA, Reddy MM. · · 2021 · cited 117× · PMID 33915740 · DOI 10.3390/molecules26071981
The potential role of Aurora kinase inhibitors in haematological malignancies.
Farag SS. · · 2011 · cited 51× · PMID 21980926 · DOI 10.1111/j.1365-2141.2011.08898.x
Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH, Zhao D, Hou J. · · 2023 · cited 32× · PMID 37110619 · DOI 10.3390/molecules28083385
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Abramson HN. · · 2016 · cited 14× · PMID 27655636 · DOI 10.18632/oncotarget.10745
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
Vats P, Saini C, Baweja B, Srivastava SK, et al · · 2025 · cited 6× · PMID 40533769 · DOI 10.1186/s12943-025-02353-3
Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach.
Bai W, Wang H, Bai H. · · 2019 · cited 6× · PMID 32099441 · DOI 10.2147/pgpm.s228574

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01145989 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 4 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01145989.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing